Scarica l'app Stockscreener
1.05
1.87%
-0.02
Dopo l'orario di chiusura:
1.03
-0.02
-1.90%
Precedente Chiudi:
$1.07
Aprire:
$1.04
Volume 24 ore:
265.35K
Relative Volume:
0.91
Capitalizzazione di mercato:
$44.64M
Reddito:
$51.13M
Utile/perdita netta:
$-93.80M
Rapporto P/E:
-0.4709
EPS:
-2.23
Flusso di cassa netto:
$-129.10M
1 W Prestazione:
-1.87%
1M Prestazione:
-9.48%
6M Prestazione:
-69.65%
1 anno Prestazione:
-74.45%
Intervallo 1D:
$1.025
$1.07
Intervallo di 1 settimana:
$0.98
$1.09
Portata 52W:
$0.98
$4.29
Repare Therapeutics Inc Stock (RPTX) Company Profile
Nome
Repare Therapeutics Inc
Settore
Industria
Telefono
(857) 412-7018
Indirizzo
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Confronta RPTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.05 | 44.64M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-06-09 | Aggiornamento | Stifel | Hold → Buy |
| 2023-02-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | Iniziato | CapitalOne | Overweight |
| 2022-04-12 | Downgrade | Stifel | Buy → Hold |
| 2022-03-17 | Ripresa | Goldman | Buy |
| 2021-09-23 | Iniziato | Stifel | Buy |
| 2021-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-28 | Iniziato | Guggenheim | Buy |
| 2021-03-01 | Iniziato | Berenberg | Buy |
| 2020-10-28 | Iniziato | Northland Capital | Outperform |
| 2020-07-14 | Iniziato | Cowen | Outperform |
| 2020-07-14 | Iniziato | Goldman | Neutral |
| 2020-07-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Repare Therapeutics Inc Borsa (RPTX) Ultime notizie
Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals
Repare Therapeutics Appoints Steve Forte CEO - citybiz
Repare Therapeutics appoints CFO as new CEO - MSN
Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal - MarketScreener
Repare Therapeutics Announces Leadership Changes in 2025 - TipRanks
Repare Therapeutics Names Forte as President, CEO - MarketWatch
Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds - TipRanks
Repare's New CEO Takes Helm With 3 Clinical Trial Readouts Coming in 2025 - Stock Titan
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock - Investing.com
Repare Therapeutics stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia
Repare Therapeutics stock hits 52-week low at $1.05 - Investing.com
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Fierce Biotech Layoff Tracker 2025: Cargo lays off 90% of staff; Empress halves workforce - Fierce Biotech
Repare therapeutics’ chief medical officer sells shares for $4,099 By Investing.com - Investing.com Australia
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga
Repare therapeutics’ chief scientific officer sells $6,396 in shares - Investing.com India
Repare therapeutics’ chief scientific officer sells $6,396 in shares By Investing.com - Investing.com South Africa
Repare therapeutics CEO Segal Lloyd Mitchell sells $24,144 in shares By Investing.com - Investing.com South Africa
Repare therapeutics CEO Segal Lloyd Mitchell sells $24,144 in shares - Investing.com
Repare Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView
HC Wainwright Issues Pessimistic Forecast for Repare Therapeutics (NASDAQ:RPTX) Stock Price - MarketBeat
What Makes Repare Therapeutics (RPTX) a New Buy Stock - Yahoo Finance
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Repare Therapeutics stock target cut to $5 at H.C. Wainwright - Investing.com India
Repare Therapeutics stock target cut to $5 at H.C. Wainwright By Investing.com - Investing.com Canada
Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare Therapeutics - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Repare Therapeutics (NASDAQ:RPTX) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
New Hires at Repare Get Stock Options as Share Price Shows 67% Drop - Stock Titan
Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation - Yahoo Finance
Repare Therapeutics Focuses on Clinical Trials Amid Restructuring - TipRanks
Repare Therapeutics Restructures and Focuses on Key Clinical Trials - MSN
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results - CRISPR Medicine News
Repare Therapeutics anticipates key trial results by late 2025 - Investing.com Canada
Repare Therapeutics Inc Azioni (RPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):